Mark N Lampert's Net Worth

$2.82 Billion

Estimate Recalculated Mar 1, 2024 07:18PM EST

Who is Mark N Lampert?

Mark N Lampert has an estimated net worth of $2.82 Billion. This is based on reported shares across multiple companies, which include RIGEL PHARMACEUTICALS INC, Cascadian Therapeutics, Inc., CATALYST BIOSCIENCES, INC., Allakos Inc., Rain Oncology Inc., ARENA PHARMACEUTICALS INC, IMMUNE DESIGN CORP., Capstone Therapeutics Corp., ChemoCentryx, Inc., DYNAVAX TECHNOLOGIES CORP, REPLIGEN CORP, KENT INTERNATIONAL HOLDINGS INC, NEUROCRINE BIOSCIENCES INC, XOMA Corp, LIGAND PHARMACEUTICALS INC, Xenon Pharmaceuticals Inc., Cullinan Oncology, Inc., Merus N.V., Nivalis Therapeutics, Inc., Repare Therapeutics Inc., PIERIS PHARMACEUTICALS, INC., Verastem, Inc., Syndax Pharmaceuticals Inc, CTI BIOPHARMA CORP, IDEAYA Biosciences, Inc., CYTOKINETICS INC, Kymera Therapeutics, Inc., Calithera Biosciences, Inc., CONCERT PHARMACEUTICALS, INC., PALATIN TECHNOLOGIES INC, MEDICINOVA INC, CytomX Therapeutics, Inc., MoonLake Immunotherapeutics, GLYCOMIMETICS INC, Principia Biopharma Inc., INFINITY PHARMACEUTICALS, INC., Eledon Pharmaceuticals, Inc., Olema Pharmaceuticals, Inc., Regulus Therapeutics Inc., ESSA Pharma Inc., 4D Molecular Therapeutics, Inc., ICAGEN INC, ADOLOR CORP, Third Harmonic Bio, Inc., Regado Biosciences Inc, FIVE PRIME THERAPEUTICS, INC., Structure Therapeutics Inc., ARRAY BIOPHARMA INC, ARQULE INC, enGene Holdings Inc., Celera CORP, FACET BIOTECH CORP, AVIGEN INC \DE, POINT Biopharma Global Inc., SUPERGEN INC, COMBINATORX, INC, and NEUROBIOLOGICAL TECHNOLOGIES INC /CA/.

SEC CIK

Mark N Lampert's CIK is 0001233840

Past Insider Trading and Trends

2011 was Mark N Lampert's most active year for acquiring shares with 122 total transactions. Mark N Lampert's most active month to acquire stocks was the month of April. 2009 was Mark N Lampert's most active year for disposing of shares, totalling 74 transactions. Mark N Lampert's most active month to dispose stocks was the month of January. 2021 saw Mark N Lampert paying a total of $132,144,944.64 for 12,405,370 shares, this is the most they've acquired in one year. In 2020 Mark N Lampert cashed out on 18,981,731.772 shares for a total of $187,629,819.78, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Allakos Inc. (ALLK) Snapshot price: $1.265

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 3
0
0
No matching records found

Rain Oncology Inc. (RAIN) No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-8.58M
0
Jan 25 - Jan 26
Form 4
+47.80%
1.71M
$5.83
$9,971,387.14
5.29M
Nov 8
Form 4
+20.43%
557.73K
$12.00
$6,692,637.85
3.29M
Jan 6 - Jan 7
Form 4
+0.41%
11.03K
$13.94
$153,828.71
2.73M
Sep 21
Form 4
+16.86%
392.27K
$16.49
$6,468,515.81
2.72M
Sep 13
Form 4
+33.73%
587K
$15.47
$9,078,692.10
2.33M
Jul 1 - Jul 6
Form 4
+7.63%
123.35K
$15.94
$1,966,334.17
1.74M
May 21 - May 24
Form 4
+14.80%
208.47K
$16.59
$3,457,720.14
1.62M
May 18 - May 19
Form 4
+4.30%
58K
$14.26
$827,167.00
1.41M
May 13
Form 4/A
+522.18%
1.13M
$16.86
$19,103,379.78
1.35M
Apr 23 - Apr 26
Form 4
4.93M
$16.86
4.93M
Apr 23 - Apr 26
Form 3
0
0
No matching records found

IMMUNE DESIGN CORP. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-15.77%
-902.00K
$1.83
-$1,653,907.20
4.82M
Dec 4
Form 3
0
0
No matching records found

Cascadian Therapeutics, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
0
0
Jun 23
Form 3
0
0
Form 4
-41.40%
-4.00M
5.66M
Feb 5
Form 4
+4.08%
378.44K
$1.82
$688,678.86
9.66M
Dec 15 - Dec 17
Form 3
0
0
Form 4
-7.41%
-554.24K
$3.24
-$1,795,731.12
6.92M
Jul 16
Form 4
+1.76%
129K
$1.78
$229,620.00
7.48M
Nov 1
Form 4
+3.64%
258.36K
$1.65
$426,166.47
7.35M
Aug 8
Form 4
+5.01%
338.09K
$1.76
$589,602.29
7.09M
Jul 31 - Aug 1
Form 4
+1.09%
214.47K
$1.79
$387,225.99
19.95M
Jun 5 - Jun 7
Form 3
0
0
No matching records found

Capstone Therapeutics Corp. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-65.68%
-4.34M
$0.06
-$260,495.16
2.27M
Jul 14
Form 4
-13.37%
-616.56K
$0.30
-$184,968.90
3.99M
Jul 1
Form 4
+4.53%
312.9K
$0.26
$81,041.10
7.23M
Sep 6
Form 4
+0.44%
78.9K
$0.26
$20,514.00
18.2M
Aug 18 - Aug 22
Form 4
+8.71%
954.25K
$0.25
$238,562.50
11.91M
Jul 28 - Jul 29
Form 4
+0.37%
18.4K
$0.25
$4,600.00
5.05M
Jul 26
Form 4
+5.28%
252.6K
$0.25
$63,099.48
5.03M
Jul 20
Form 4
+4.70%
358.6K
$0.25
$89,344.99
7.99M
Jul 14 - Jul 18
Form 4
+0.28%
9K
$0.25
$2,250.00
3.19M
Jul 11
Form 4
+0.09%
4.7K
$0.25
$1,171.72
5.24M
Jun 30
Form 4
+1.95%
100.05K
$0.25
$24,990.49
5.24M
Jun 27 - Jun 29
No matching records found